Fgfr3 Fibroblast Growth Factor Receptor 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Fibroblast Growth Factor Receptor 3 (FGFR3) is a receptor tyrosine kinase (RTK) that plays critical roles in skeletal development, tissue maintenance, and cellular proliferation. FGFR3 belongs to the FGFR family (FGFR1-4), which binds fibroblast growth factors (FGFs) to activate downstream signaling cascades controlling cell survival, differentiation, and migration. While FGFR3 is best known for its role in bone and cartilage development—where gain-of-function mutations cause skeletal dysplasias like achondroplasia—emerging evidence links FGFR3 to neuronal function and neurodegeneration. FGFR3 signaling affects neurogenesis, oligodendrocyte development, and synaptic plasticity, with dysregulation implicated in Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
| Fibroblast Growth Factor Receptor 3 |
|---|
| Gene Symbol | FGFR3 |
| Full Name | Fibroblast Growth Factor Receptor 3 |
| Chromosome | 4p16.3 |
| NCBI Gene ID | 2261 |
| OMIM | 134934 |
| Ensembl ID | ENSG00000068078 |
| UniProt ID | P22607 |
| Associated Diseases | Achondroplasia, Thanatophoric dysplasia, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis |
¶ Gene Structure and Protein
The FGFR3 gene spans approximately 16.5 kb on chromosome 4p16.3 and consists of 19 exons encoding a transmembrane receptor tyrosine kinase of 808 amino acids. FGFR3 follows the classic RTK architecture:
¶ Protein Domains
- Extracellular Domain: Contains three immunoglobulin-like domains (D1-D3) that mediate FGF binding
- Transmembrane Domain: Single helix anchoring the receptor in the plasma membrane
- Juxtamembrane Domain: Regulatory region
- Tyrosine Kinase Domain: Catalytic domain with kinase activity (residues 456-759)
FGFR3 undergoes alternative splicing generating multiple isoforms:
- FGFR3-IIIb: Epithelial isoform, binds FGF1, FGF3, FGF7, FGF10, FGF22
- FGFR3-IIIc: Mesenchymal isoform, binds FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF17, FGF18
- Soluble FGFR3: Truncated isoform acting as a decoy receptor
FGFR3 is activated by binding of fibroblast growth factors (FGFs), leading to:
Dimerization and Autophosphorylation: FGF binding induces receptor dimerization and trans-autophosphorylation of tyrosine residues
Downstream Signaling Cascades:
- RAS/MAPK pathway: Cell proliferation and differentiation
- PI3K/AKT pathway: Cell survival and metabolism
- PLCγ pathway: Calcium signaling and cytoskeletal reorganization
- STAT pathway: Transcriptional regulation
- Skeletal development: Negative regulator of bone growth
- Cartilage formation: Essential for endochondral ossification
- Vertebrae development: Segmental patterning
- Inner ear development: Otic capsule formation
In the nervous system, FGFR3 participates in:
Neurogenesis: FGF signaling through FGFR3 regulates neural stem cell proliferation and differentiation
Oligodendrocyte Development: FGFR3 is expressed in oligodendrocyte precursor cells (OPCs) and promotes:
- OPC proliferation
- Myelination
- Oligodendrocyte survival
Synaptic Plasticity: FGFR3 modulates:
- Long-term potentiation (LTP)
- Dendritic spine morphology
- Synaptic protein expression
Neuronal Survival: FGFR3 provides neurotrophic support through AKT-mediated anti-apoptotic signaling
FGFR3 has complex, stage-dependent roles in Alzheimer's disease:
Early Stage: FGFR3 activation may be protective:
- Neurotrophic support for cholinergic neurons
- Enhancement of synaptic plasticity
- Promotion of adult neurogenesis
Late Stage: FGFR3 dysregulation may contribute to pathology:
- Altered FGF signaling in AD brain
- FGFR3 interacts with amyloid precursor protein (APP) processing
- Dysregulated FGFR3 may affect tau phosphorylation
Therapeutic Potential: FGFR3 modulators are being investigated for AD:
- FGFR3 agonists may support neuronal survival
- FGFR3 antagonists may reduce pathological signaling
FGFR3 involvement in PD includes:
Dopaminergic Neuroprotection: FGF signaling through FGFR3 supports:
- Survival of substantia nigra dopaminergic neurons
- Tyrosine hydroxylase expression
- Dendritic arborization
Glial Function: FGFR3 in astrocytes and microglia:
- Modulates neuroinflammation
- Affects alpha-synuclein clearance
FGFR3 plays important roles in demyelinating diseases:
Oligodendrocyte Precursor Cell (OPC) Biology:
- FGFR3 promotes OPC proliferation and differentiation
- FGFR3 signaling is necessary for remyelination
- FGFR3 expression decreases in chronic MS lesions
Therapeutic Potential:
- FGFR3 agonists may enhance remyelination
- FGFR3 represents a target for MS drug development
- Amyotrophic lateral sclerosis (ALS): FGFR3 dysregulation in motor neurons
- Huntington's disease: Altered FGF/FGFR signaling
- Glaucoma: FGFR3 in retinal ganglion cell survival
FGFR3 is expressed in:
- Cartilage and bone: Highest expression in chondrocytes
- Brain: Cortex, hippocampus, cerebellum, basal ganglia
- Kidney: Epithelial cells
- Skin: Epidermal keratinocytes
In neurons:
- Somatic membrane
- Dendritic shafts
- Growth cones
- Synaptic membranes
In glia:
- Astrocytes (reactive)
- Oligodendrocyte precursor cells
- Mature oligodendrocytes
FGFR3 mutations cause several skeletal disorders:
| Disorder |
Mutation |
Phenotype |
| Achondroplasia |
G380R (gain-of-function) |
Rhizomelic dwarfism |
| Thanatophoric dysplasia |
Multiple |
Lethal skeletal dysplasia |
| Hypochondroplasia |
N540K |
Mild dwarfism |
| Crouzon syndrome |
Multiple |
Craniosynostosis |
FGFR3 is frequently mutated in:
- Bladder carcinoma (~60% of cases)
- Multiple myeloma
- Cervical cancer
While FGFR3 mutations are not causative for neurodegeneration:
- Altered expression in AD/PD brains
- Association studies suggest modifying effects
- FGFR3 signaling modifications in disease states
| Compound |
Mechanism |
Status |
| BGJ398 (Infigratinib) |
FGFR1-3 TKI |
Phase 3 (cancer) |
| NVP-BGJ398 |
FGFR3-selective |
Preclinical |
| PRO-001 |
FGFR3 antibody |
Preclinical |
| Recombinant FGFs |
FGFR3 agonists |
Research |
- FGFR3 agonists: Neuroprotection, enhanced neurogenesis
- FGFR3 antagonists: May reduce pathological signaling
- FGF2/FGFR3 combinations: Synergistic effects
¶ Interactions and Pathways
FGF Ligand → FGFR3 → FRS2 → GRB2/SOS → RAS → RAF → MEK → ERK
↓
PI3K → AKT → mTOR
- FGF1, FGF2, FGF9, FGF18: Primary ligands
- FRS2α: Docking protein
- GRB2: Adaptor protein
- PIK3R1 (p85): Regulatory subunit
- PTPN11 (SHP2): Phosphatase
- APP processing: FGFR3 affects amyloid production
- Tau pathology: Modulates kinase signaling
- Neuroinflammation: Regulates cytokine expression
- Fgfr3⁻/⁻ mice: Viable with skeletal overgrowth
- Fgfr3 conditional knockout: Tissue-specific deletion studies
- Neural-specific knockout: Neurodevelopmental phenotypes
- Achachondroplasia models: G380R knock-in
- AD models crossed with FGFR3 mutants: Interaction studies
- Immunohistochemistry: Localize FGFR3 in tissue
- Western blot: Detect protein expression
- ELISA: Measure ligand binding
- Co-immunoprecipitation: Identify interactions
- CRISPR-Cas9: Genetic manipulation
- Single-cell RNA-seq: Expression in specific cell types
Fgfr3 Fibroblast Growth Factor Receptor 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Fgfr3 Fibroblast Growth Factor Receptor 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Horton WA, et al. (2007). FGFR3. Am J Med Genet A. 143A(21):2482-2488
- Eswarakumar VP, et al. (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16(2):139-149
- Wang Y, et al. (2015). FGFR3 deficiency causes abnormal brain development. J Mol Neurosci. 57(3):400-409
- Klamer G, et al. (2015). Fibroblast growth factor receptor 3 (FGFR3) signaling is involved in neural induction. Dev Neurobiol. 75(10):1131-1142
- Fortress AM, et al. (2013). Fibroblast growth factor 14 and the neurodegenerative cascade. Neurobiol Learn Mem. 105:225-246
- Sims JR, et al. (2009). FGF2/FGFR signaling in oligodendrocyte development. J Neurosci. 29(41):12899-12905
- Nicoli ER, et al. (2020). FGFR3 signaling and role in multiple sclerosis. Cells. 9(6):1476
- Chu J, et al. (2019). FGFR3 in Alzheimer's disease: Friend or foe? Prog Neuropsychopharmacol Biol Psychiatry. 95:109679